Peptides have graduated from niche biohacking interest to mainstream pharmaceutical territory, with government officials and media figures now backing their accessibility. The FDA is poised to consider whether pharmacies should be permitted to mix custom peptide formulations, a shift that would overturn restrictions imposed in 2023. Career scientists within the agency have advised against the change, yet many observers expect approval anyway, particularly because the assessment committee includes peptide advocates.

Major telehealth and pharmacy companies are already mobilising for market entry, having acquired manufacturing capacity and invested six-figure sums in product development and safety protocols. This mirrors the commercial opportunity seen in the GLP-1 medication boom, which normalised self-administered injectable treatments. Even with regulatory approval, the pathway forward involves an extended review period where the FDA will propose operating rules and accept public feedback, delaying any immediate commercial launch.